We are live on ! Find out more
WST icon

West Pharmaceutical

205 hedge funds and large institutions have $2.55B invested in West Pharmaceutical in 2013 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 75 increasing their positions, 84 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

17% more capital invested

Capital invested by funds: $2.19B → $2.55B (+$364M)

4% more funds holding

Funds holding: 197205 (+8)

2.43% less ownership

Funds ownership: 180.46%178.02% (-2.4%)

11% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 84

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
205
Holders Change
+8
Holders Change %
+4.06%
% of All Funds
6.65%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.19%
New
23
Increased
75
Reduced
84
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Neuberger Berman Group
1
Neuberger Berman Group
New York
$214M -$5.87M -153,922 -3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$210M +$16.2M +425,085 +9%
Franklin Resources
3
Franklin Resources
California
$193M -$8.48M -222,212 -5%
BFA
4
BlackRock Fund Advisors
California
$155M +$16M +420,467 +13%
KI
5
Kalmar Investments
Delaware
$81.8M -$570K -14,940 -0.7%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$80.2M +$5.67M +148,600 +8%
BIT
7
BlackRock Institutional Trust
California
$77.1M -$275K -7,219 -0.4%
GIM
8
Granahan Investment Management
Massachusetts
$68.7M +$1.76M +46,200 +3%
State Street
9
State Street
Massachusetts
$65.7M +$754K +19,756 +1%
BTW
10
Boston Trust Walden
Massachusetts
$64.9M -$1.91M -50,173 -3%
BAMCO Inc
11
BAMCO Inc
New York
$62M +$32.7M +858,222 +133%
CIP
12
Champlain Investment Partners
Vermont
$61.4M -$27.8M -728,780 -33%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$53.6M +$6.72M +176,120 +16%
Fisher Asset Management
14
Fisher Asset Management
Washington
$52.5M -$1.66M -43,580 -3%
DIA
15
Denver Investment Advisors
Colorado
$48.6M -$15.2M -397,999 -25%
RCG
16
Ruane, Cunniff & Goldfarb
New York
$44.5M -$1.58M -41,449 -4%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$44.2M -$8.78M -230,107 -18%
Invesco
18
Invesco
Georgia
$40.4M +$4.2M +110,151 +13%
GKIM
19
GW&K Investment Management
Massachusetts
$39.1M +$5.2M +136,188 +17%
RIM
20
RS Investment Management
California
$38.7M +$23.5M +615,672 +190%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$38.6M -$1.72M -45,092 -5%
SAM
22
Silvercrest Asset Management
New York
$38.3M +$1.8M +47,294 +5%
Lord, Abbett & Co
23
Lord, Abbett & Co
New Jersey
$35.1M -$16.9M -442,500 -34%
Fidelity Investments
24
Fidelity Investments
Massachusetts
$32.1M +$29.7M +779,497 New
ICM
25
IronBridge Capital Management
Illinois
$31.7M -$637K -16,700 -2%

WST Hedge Fund Activity: Q3 2013 in Review

205 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2013, worth a combined $2.55B — up 17% from $2.19B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new WST positions and 13 closed out — a net gain of 10 holders — while 75 added to existing stakes and 84 trimmed.

The largest buyer was BAMCO Inc, adding an estimated $32.7M. The largest seller was Hermes Investment Management, cutting an estimated $28.5M.

  • 205 institutional investors held West Pharmaceutical (WST) as of Q3 2013, up from 197 in Q2 2013.
  • Funds reported $2.55B of West Pharmaceutical stock for Q3 2013, up 17% quarter-over-quarter.
  • 23 funds opened new West Pharmaceutical positions in Q3 2013 and 13 closed out, a net change of +10 holders.
  • The largest West Pharmaceutical buyer in Q3 2013 was BAMCO Inc, an estimated $32.7M added.
  • The largest West Pharmaceutical seller in Q3 2013 was Hermes Investment Management, an estimated $28.5M sold.

Based on aggregated 13F filings for Q3 2013.